JASON EHRLICH - 20 Oct 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Role
Chief Medical Officer and Chief Development Officer
Signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Issuer symbol
KOD
Transactions as of
20 Oct 2021
Net transactions value
-$705,309
Form type
4
Filing time
22 Oct 2021, 16:52:24 UTC
Previous filing
22 Sep 2021
Next filing
24 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KOD Common Stock Options Exercise $71,516 +6,950 +13% $10.29 58,491 20 Oct 2021 Direct
transaction KOD Common Stock Sale $635,681 -5,698 -9.7% $111.56* 52,793 20 Oct 2021 Direct F1, F2
transaction KOD Common Stock Sale $141,144 -1,252 -2.4% $112.73* 51,541 20 Oct 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KOD Stock Option (Right to Buy) Options Exercise $0 -6,950 -2.8% $0.000000 239,388 20 Oct 2021 Common Stock 6,950 $10.29 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $111.16 to $112.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
F3 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $112.23 to $113.16, inclusive.
F4 Twenty-five percent of the shares subject to the option vested on September 1, 2019, and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

Remarks:

Chief Medical Officer and Chief Development Officer